GTx, Inc. Announces Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium of Additional Study Results from the Phase III Clinical Trial Evaluating Toremifene 80 mg for the Reduction of Fractures in Men with Prostate Can

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures in men with prostate cancer on androgen deprivation therapy will be presented this afternoon at the 2011 ASCO Genitourinary Cancers Symposium being held in Orlando, Florida.